Although the majority of patients with Hodgkin's lymphoma (HL) are cured with primary therapy, between 20 and 30% of advanced-stage patients relapse after completion of treatment. If eligible, these patients proceed towards a curative auto-SCT (ASCT). Unfortunately, long-term follow-up shows that up to 50% of patients relapse after ASCT. Various treatments have been used in the post-ASCT setting, ranging from simple chemotherapy to aggressive transplant-based strategies. Myeloablative allo-SCT in HL has been used in advanced phases of the disease, but there have been significant concerns since the treatment-related mortality often exceeded 50% and relapses were not uncommon. 1 The presence of a clinically significant graft-vs-HL effect had never been clearly shown until more recent reports described signs of an antitumour effect after donor lymphocyte infusion. 2, 3 In addition to this demonstration of immune-mediated antitumour effect, the early treatment-related mortality of allogeneic transplantation has improved with the use of reduced-intensity conditioning allo-SCT (RIC-allo) strategies. [4] [5] [6] We performed a retrospective review of RIC-allo for relapsed or refractory HL performed at transplant centers in Canada between June 1999 and December 2006. This report includes 29 consecutive patients with HL who underwent RIC allo-SCT. The RIC allo-SCT procedure was defined in a similar manner as the recent Center for International Blood and Marrow Transplant Research (CIBMTR) workshop, but included patients who received up to 12.8 mg/kg of IV BU. 7 We believed that all of these regimens were similar in their low TRM and early nonhematological toxicity. Various preparative regimens were used as institutional practice varied across the country. All regimens were fludarabine based. A variety of GVHD prophylaxis strategies were used along with local institutional supportive care measures. Twenty-one patients underwent matched sibling transplantation with eight matched unrelated donor transplants. The median age at the time of RIC-allo was 26 years (range 14-45). All but one patient had undergone previous ASCT, with 10 of 29 cases having had at least four lines of therapy before allo-SCT. Twenty-six patients (90%) had received radiotherapy earlier. Of the 29 cases, 28 had responsive disease at the time of RIC-allo transplant. With a median follow-up of 2.3 years (range 0.7-7.6 years), 15 deaths occurred (10 due to relapsed HL and 5 due to treatment-related causes). The 3-year estimate for OS is 42% (95% confidence intervals 26-67%, see Figure 1 ), whereas the 3-year estimated disease-free survival is 19% (95% confidence intervals 9-44%). Twenty relapses were observed and two patients died in remission due to treatment toxicity. A univariate analysis of prognostic factors for survival was carried out with no statistically significant factors identified (Table 1) .
Currently, allogeneic transplantation is typically reserved for patients with HL who have failed previous autologous transplantation or for patients who are chemoresistant or deemed to be at high risk of treatment failure with ASCT. There is no standardized approach to the management of relapsed HL after ASCT or for therapy-refractory HL, but a variety of treatments are used in this setting. 8 As all these therapies are generally palliative, except for allotransplant, they are unappealing given the young age and general medical fitness of the majority of patients with HL. Thus, it remains an important clinical challenge to best prioritize patients towards conventional therapies, novel agents and allogeneic transplantation.
Accepting that an appropriate group of patients can be identified to pursue an allo-SCT strategy, the intensity of the preparative regimen and varying GVHD prophylaxis regimens have been studied in a retrospective manner. The European Group for Blood and Marrow Transplantion (EBMT) has performed a retrospective registry review of 168 cases comparing myeloablative and RIC-allo procedures and reports a hazard ratio (HR) of 2.85 favouring RIC-allo for nonrelapse mortality (Po0.001) and a similar HR of 2.05 for OS (P ¼ 0.04). 6 A retrospective cohort comparison of a phase II series from the United Kingdom using alemtuzumab with CYA as GVHD prophylaxis and a phase II series from Spain using CYA and MTX showed an improvement in nonrelapse mortality and reduced rates of chronic GVHD with alemtuzumab. Overall survival and PFS were not significantly different. 3 No regimen has emerged as clearly superior and transplant centers will likely continue to use institutionspecific RIC-allo protocols, although the intensity and antilymphoma properties of these regimens vary considerably. Whether these differences affect survival remains unknown and is certainly worthy of further study.
The role of allotransplant has not undergone a randomized comparison with standard therapy; an attempt to provide some controlled data was reported by the UK cooperative group. Thomson et al. 9 performed a retrospective matched comparison of patients undergoing RICallo with historical controls who had survived for at least 1 year following relapse after ASCT, and the reported survival was improved both from the time of diagnosis and after ASCT in RIC-allo patients. Although these data are interesting, it is hypothesis generating and suffers from the usual methodological limitations of retrospective cohort comparisons.
The CBMTG experience provides a national review that is similar to other international reports estimating 25-30% PFS and 35-60% OS at 2 years after SCT. 6 Our 3-year estimates of OS, PFS and TRM (42, 19 and 18%) are consistent with those reported by other groups and clearly the benefit of RIC-allo to patients with relapsed/refractory HL remains open to debate. We conclude that RIC-allo for relapsed or refractory HL after ASCT requires further investigation and should be considered in the context of a clinical trial.
As there have been no randomized trials in patients who have failed ASCT, decisions for specific patients should be individualized. Other treatment options to be considered for individual patients include radiotherapy, standard palliative regimens and experimental therapies. Further research in this area should include the development of novel transplant regimens that focus on strategies to improve disease control.
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